bioecon Member area
Technology · Health & biomedicine / Specialty & fine chemicals

Large-Scale Solid-Phase and Liquid-Phase Therapeutic Peptide Synthesis

Industrial scale multi-kilogram peptide manufacturing combining microwave-enhanced automated solid-phase peptide synthesis (SPPS), convergent liquid-phase fragment condensation (LPPS), and large-bore preparative HPLC, synthesizing complex therapeutic peptides, pseudoprolines, and unnatural amino acid derivatives from grams to hundreds of kilograms.

1 · What it gives

Large-scale solid-phase peptide synthesis (SPPS) and liquid-phase peptide synthesis (LPPS) constitute the industrial backbone for manufacturing high-complexity peptide APIs, cyclic peptide antibiotics, and metabolic GLP-1/GIP agonists. The technology has evolved from manual laboratory polystyrene resin coupling to automated, multi-ton automated batch reactors operating under green chemistry principles. The paradigm relies on orthogonal protective group strategies—primarily base-labile Fmoc (9-fluorenylmethoxycarbonyl) for N-terminal protection and acid-labile tert-butyl (tBu/Boc) for side-chain moieties.

Modern industrial peptide manufacturing utilizes green alternative solvents (such as Cyrene, gamma-valerolactone [GVL], and 2-methyltetrahydrofuran) to replace toxic dimethylformamide (DMF) and N-methyl-2-pyrrolidone (NMP). Coupled with microwave-assisted heating and continuous-flow coupling engines using Oxyma Pure / DIC or COMU activators, coupling cycles are shortened from hours to under 6 minutes with racemization rates below 0.05%. Final cleavage with trifluoroacetic acid (TFA) and scavenger cocktails, followed by dynamic axial compression (DAC) preparative RP-HPLC, yields kilograms of API with purity >99.0% and overall process mass intensity (PMI) reduced by 65%.

The key directions of this technology are:

  1. Green Solvent & Low-PMI Peptide Synthesis: Replacing hazardous reproductive toxins (DMF, DCM, NMP) with bio-based green solvents (Cyrene, GVL, cyclopentyl methyl ether) to achieve Process Mass Intensity (PMI) reductions >60%.
  2. Continuous Flow & Microwave-Accelerated Coupling: Deploying continuous flow micro-reactors and microwave cavity irradiation to accelerate sterically hindered peptide bond formations to <5 minutes per residue.
  3. Liquid-Phase Peptide Synthesis (LPPS) for Cyclic Scaffolds: Utilizing hydrophobic tag-assisted LPPS and chemo-enzymatic peptide cyclization to produce multi-kilogram batches of cyclic macrocycles (e.g. KRAS inhibitors, cyclosporin analogues).
  4. Industrial Preparative RP-HPLC & Solvent Recycling: Scaling dynamic axial compression columns (up to 1,000 mm diameter) packed with 10 µm C18/C8 silica with automated inline falling-film solvent distillation recycling >90% of acetonitrile.

Sectoral value chain#

┌────────────────────────────────────────────────────────┐
│  Tier 1: Protected Amino Acid Monomers & Green Solvents │
│  (Fmoc-amino acids, Oxyma Pure, Cyrene, GVL, resin)    │
└───────────────────────────────────┬────────────────────┘
                                    │
                                    ▼
┌────────────────────────────────────────────────────────┐
│  Tier 2: Automated SPPS / LPPS Peptide Elongation      │
│  (Multi-ton batch synthesis, continuous-flow coupling) │
└───────────────────────────────────┬────────────────────┘
                                    │
                                    ▼
┌────────────────────────────────────────────────────────┐
│  Tier 3: Acidolytic Cleavage & Crude Deprotection      │
│  (TFA / TIS / water scavenger cocktail, precipitation) │
└───────────────────────────────────┬────────────────────┘
                                    │
                                    ▼
┌────────────────────────────────────────────────────────┐
│  Tier 4: Preparative RP-HPLC & Ion-Exchange Polishing  │
│  (DAC columns, diastereomer resolution, solvent recovery)│
└───────────────────────────────────┬────────────────────┘
                                    │
                                    ▼
┌────────────────────────────────────────────────────────┐
│  Tier 5: Lyophilization & Compendial API Release       │
│  (USP / Ph. Eur. quality, acetate/chloride salt exchange)
└────────────────────────────────────────────────────────┘

Value chain levels#

LevelDescriptionKey inputs/outputs
Protected Amino Acid Building BlocksMulti-kilogram synthesis of stereochemically pure L- and D-Fmoc-amino acids with acid-labile protection (Trt, Pbf, OtBu) and chiral purity >99.8%.In: Natural and unnatural amino acids, Fmoc-Cl, protecting reagents.
Out: Compendial Fmoc-amino acid crystalline powders with <0.1% D-enantiomer.
Automated Chain Elongation (SPPS / LPPS)Successive deprotection and amino acid coupling on polystyrene-DVB or ChemMatrix resin beads in multi-thousand-liter automated peptide reactors.In: Fmoc monomers, Oxyma/DIC coupling cocktails, green solvents.
Out: Resin-bound fully protected linear or branched polypeptide intermediates.
Global Cleavage & DeprotectionAcidolytic deprotection using 90–95% trifluoroacetic acid with triisopropylsilane (TIS) and ethanedithiol (EDT) scavengers, followed by cold ether precipitation.In: Peptide-resin conjugate, TFA cleavage cocktail, diisopropyl ether.
Out: Crude peptide precipitate with purity 70–85% ready for chromatography.
Preparative Reverse-Phase HPLC PolishingDual-stage purification on dynamic axial compression (DAC) columns packed with 10–15 µm spherical C18 silica using TEAP/ammonium acetate gradients.In: Crude peptide solution, chromatography solvents, ion exchange resins.
Out: Purified peptide fraction pools with >99.0% chromatographic purity and <0.2% single impurity.
Lyophilization & Compendial Release TestingBulk freeze-drying in cGMP cleanroom lyophilizers, automated salt exchange from trifluoroacetate to acetate, and quality release testing.In: Purified peptide solution, acetic acid, water for injection.
Out: Sterile compendial peptide API powder compliant with ICH Q7 standards.

Cross-cutting technologies of the sector:

  • Process Mass Intensity (PMI) Optimization: Drives green engineering benchmarks across pharma manufacturing by reducing solvent and raw material footprints.
  • High-Resolution Mass Spectrometry (HRMS): Identifies single-deletion, insertion, and racemized sequence variants during in-process batch release.
  • Dynamic Axial Compression (DAC) Chromatography: Maintains uniform bed packing and zero wall channeling in industrial-scale 600–1,000 mm diameter columns.

2 · What it replaces 3 · matched by industry

3 · How to implement 4 steps

  1. 1
    Fmoc-solid phase peptide synthesis (SPPS) automation
    Coupling protected amino acids stepwise onto pre-swelled polystyrene resins in large-scale stirred glass reactors using DIC/Oxyma activation.
  2. 2
    Microwave and thermal coupling acceleration
    Applying regulated microwave or thermal energy to untangle hydrophobic peptide aggregates, achieving >99% single-step coupling conversion of recalcitrant sequences.
  3. 3
    Convergent liquid-phase fragment condensation
    Condensing protected peptide segments in solution to assemble long-chain therapeutic polypeptides while minimizing deletion impurities.
  4. 4
    Industrial axial-compression preparative HPLC purification
    Purifying crude peptides on 300-600 mm dynamic axial compression (DAC) C18 columns with orthogonal ion-pair acetonitrile gradients, followed by lyophilization.

4 · Who delivers

Matched suppliers (matched automatically)

GenScript ProBio / GenscriptChinaServices / consultingactive
A.COSTANTINO & C SPAItalyProduceractive
IsomeraseUnited KingdomProduceractive
QINGDAO SEAWIN BIOTECH GROUPChinaProduceractive
SafecoteUnited KingdomProduceractive
21st.BIODenmarkProduceractive
Shin-Etsu ChemicalJapanProduceractive

Leading companies and institutes (from the brief)

Company / InstituteCountryKey products / platformsTech featuresStatus 2026
Bachem🇨🇭 SwitzerlandCustom Peptide API & Large-Scale SPPSWorld’s leading peptide manufacturing CDMO with multi-ton automated solid-phase capacity and green chemistry leadershipcommercial
PolyPeptide Group🇸🇪 Sweden / 🇧🇪 BelgiumSolid-Phase & Liquid-Phase Peptide SynthesisPremier global contract manufacturer delivering clinical and commercial APIs across 6 global GMP facilitiescommercial
CordenPharma🇩🇪 GermanyIntegrated Peptide API & Lipid CDMOSpecialized in large-scale multi-kilogram peptide synthesis and peptide-lipid conjugate formulationcommercial
WuXi AppTec🇨🇳 ChinaWuXi TIDES Peptide & Oligo PlatformMassive global contract manufacturing platform with over 10,000 L of automated peptide synthesis capacitycommercial
Shilpa CDMO🇮🇳 IndiaCommercial Peptide Manufacturing SuiteExpanding commercial CDMO with continuous flow and large-scale preparative HPLC peptide suitescommercial
AmbioPharm🇺🇸 United States / 🇨🇳 ChinaHybrid SPPS/LPPS ManufacturingMajor commercial supplier of high-purity generic and innovative therapeutic peptide APIscommercial

5 · Rules & route to market

Route into Russia / EAEU: EAC · EAEU accredited bodies / Rosakkreditatsiya
declaration registered within 3 working days (testing extra); certification longer
Information, not legal advice — confirm the procedure for your product. (2026-10-06)
United States

FDA ANDA Synthetic Peptide Guidance & Domestic Capacity Expansion#

  • The US FDA maintains stringent guidance on ANDAs for synthetic peptides referencing recombinant originators (glucagon, liraglutide, semaglutide), permitting 505(j) approvals only when synthetic peptide-related impurities do not exceed 0.50% and novel impurities remain below 0.10%.
  • US biopharma reshoring initiatives and BARDA biodefense grants drive massive investments into domestic continuous peptide synthesis facilities in the Research Triangle and New Jersey.
  • American CDMOs aggressively pioneer tag-assisted liquid-phase peptide synthesis (LPPS) to lower manufacturing costs for high-volume commercial metabolic peptides.

European Union

European Green Deal Chemistry & EMA CHMP Synthesis Guidelines#

  • Europe—anchored by world leaders Bachem in Switzerland, PolyPeptide Group in Sweden/Belgium, and CordenPharma in Germany—is the premier quality center for complex commercial peptides.
  • EMA guidelines on the manufacture of synthetic peptides (EMA/CHMP/CVMP/QWP/367182/2025) require rigorous tracking of deletion and insertion peptides through high-resolution LC-MS/MS.
  • European chemical sustainability mandates under REACH drive rapid industrial transition toward circular solvent recycling and zero-discharge peptide factories.

China

Global API Supply Leadership & Green Synthesis Transition#

  • China produces over 60% of the world’s commercial protected amino acid raw materials and peptide building blocks, centered in industrial clusters across Jiangsu, Zhejiang, and Sichuan.
  • Leading Chinese CDMOs (WuXi AppTec, Hybio, AmbioPharm) operate automated 5,000-liter solid-phase synthesis reactors, achieving multi-ton annual capacity for GLP-1 APIs.
  • The Ministry of Ecology and Environment and NMPA strictly mandate the phase-out of DMF and DCM solvents, accelerating industrial adoption of bio-based Cyrene and continuous flow technologies.

6 · Money: tenders & grants

7 · Tech stack & innovations

  1. Automated Reactor Mechanics & Process Controls:
    • Hastelloy C-22 automated batch peptide reactors (500 L to 5,000 L) equipped with low-shear paddle impellers and nitrogen purging.
    • Real-time photometric UV monitoring tracking Fmoc deprotection completeness (absorbance of dibenzofulvene-piperidine adduct at 301 nm).
    • Automated solvent distribution manifolds delivering precise reagent stoichiometry with <0.5% dispensing error.
  2. Coupling Kinetics & Green Solvent Performance:
    • Coupling cocktails utilizing Oxyma Pure (ethyl 2-cyano-2-(hydroxyimino)acetate) and diisopropylcarbodiimide (DIC) in 1:1 Cyrene:cyclopentyl methyl ether.
    • Coupling yields exceeding 99.8% per residue in <15 minutes at 45°C without elevated optical racemization (D-amino acid <0.05%).
    • Total process mass intensity (PMI) reduced from 4,500 kg solvent/kg API down to 1,200 kg/kg via inline falling-film solvent recovery.
  3. Preparative Chromatography & Salt Metathesis:
    • Dynamic axial compression (DAC) preparative chromatography columns (400–1,000 mm ID) packed with 10 µm 120 Å spherical C18 silica.
    • Continuous gradient fractionation with ammonium acetate / acetonitrile mobile phase achieving baseline separation of n-1 deletion sequences.
    • Automated inline ion exchange resin metathesis converting trifluoroacetate counterions into physiological acetate with TFA residue <0.1%.

Sources 1 · 0 independent · 1 producer sites

Producers' own sites 1

  1. www.swissbiotech.org producer checked 2026-11-22